- Home
- PMO vs XOMA Comparison
PMO vs XOMA Comparison
Compare PMO & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMO
- XOMA
- Stock Information
- Founded
- PMO 1993
- XOMA 1981
- Country
- PMO United States
- XOMA United States
- Employees
- PMO N/A
- XOMA N/A
- Industry
- PMO Finance Companies
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- PMO Finance
- XOMA Health Care
- Exchange
- PMO Nasdaq
- XOMA Nasdaq
- Market Cap
- PMO 287.4M
- XOMA 330.2M
- IPO Year
- PMO N/A
- XOMA N/A
- Fundamental
- Price
- PMO $9.72
- XOMA $25.83
- Analyst Decision
- PMO
- XOMA Strong Buy
- Analyst Count
- PMO 0
- XOMA 2
- Target Price
- PMO N/A
- XOMA $69.50
- AVG Volume (30 Days)
- PMO 99.0K
- XOMA 59.0K
- Earning Date
- PMO 01-01-0001
- XOMA 08-12-2025
- Dividend Yield
- PMO 4.10%
- XOMA N/A
- EPS Growth
- PMO N/A
- XOMA N/A
- EPS
- PMO 0.42
- XOMA N/A
- Revenue
- PMO N/A
- XOMA $42,909,000.00
- Revenue This Year
- PMO N/A
- XOMA $70.91
- Revenue Next Year
- PMO N/A
- XOMA $14.00
- P/E Ratio
- PMO $24.38
- XOMA N/A
- Revenue Growth
- PMO N/A
- XOMA 638.41
- 52 Week Low
- PMO $8.57
- XOMA $18.35
- 52 Week High
- PMO $10.68
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- PMO 36.59
- XOMA 48.34
- Support Level
- PMO $9.72
- XOMA $25.42
- Resistance Level
- PMO $9.78
- XOMA $26.63
- Average True Range (ATR)
- PMO 0.08
- XOMA 0.89
- MACD
- PMO -0.02
- XOMA -0.19
- Stochastic Oscillator
- PMO 3.85
- XOMA 12.50
About PMO Putnam Municipal Opportunities Trust
Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.